JLE

Innovations & Thérapeutiques en Oncologie

MENU

Present and future management with immunotherapy in metastatic non-small cell lung cancer Volume 4, issue 4, July-August 2018

  • [1] Garon E.B., Rizvi N.A., Hui R. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028. 21
  • [2] Rizvi N.A., Mazières J., Planchard D. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257-265. 3
  • [3] Rittmeyer A., Barlesi F., Waterkamp D. Atezolizumab docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial. Lancet. 2017;389:255-265. versus10066
  • [4] Brahmer J., Reckamp K.L., Baas P. Nivolumab Docetaxelin advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135. versus2
  • [5] Borghaei H., Paz-Ares L., Horn L. Nivolumab Docetaxelin advanced non squamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639. versus17
  • [6] Herbst R.S., Baas P., Kim D.W. Pembrolizumab docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550. versus10027
  • [7] Reck M, Taylor F, Penrod JR, et al. Impact of Nivolumab versus Docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: Results from the CheckMate 017 Study. J Thorac Oncol 2017 pii : S1556-0864 (17) 32878-2.
  • [8] Rizvi N.A., Hellmann M.D., Snyder A. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128. 6230
  • [9] Herbst R.S., Soria J.C., Kowanetz M. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567. 7528
  • [10] Gridelli C., Besse B., Brahmer J.R., Crino L., Felip E., de Marinis F. The evolving role of nivolumab in non-small-cell lung cancer for second-line treatment: A new cornerstone for our treatment algorithms. Results from an international experts panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2016;17:161-168. 3
  • [11] Ramos-Esquivel A., van der Laat A., Rojas-Vigott R., Juárez M., Corrales-Rodríguez L. Anti-PD-1/anti-PD-L1 immunotherapy docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open. 2017;2:e000236. versus3
  • [12] Felip Font E., Gettinger S.N., Burgio M.A. Three-year follow-up from CheckMate 017/057: Nivolumab docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2017;28:1301PD. versusSuppl. 5
  • [13] Girard N., Audigier Valette C., Cadranel J. IFCT-1502 CLINIVO: Real-life experience with nivo- lumab in 600patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP). Ann Oncol. 2017;28:1302PD. Suppl. 5
  • [14] Popat S., Ardizzoni A., Ciuleanu T. Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged 6 70 years and with poorperformances status. Ann Oncol. 2017;28:1303PD. Suppl. 5
  • [15] Passiglia F., Galvano A., Rizzo S. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pem- brolizumaband atezolizumab. In t J Cancer. 2018;142:1277-1284. 6
  • [16] Pillai R.N., Behera M., Owonikoko T.K. Comparison of the toxicity profile of PD-1 PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018;124:271-277. versus2
  • [17] Gettinger S., Rizvi N.A., Chow L.Q. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2980-2987. 25
  • [18] Reck M., Rodriguez-Abreu D., Robinson A.G. Pembrolizumab chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833. versus19
  • [19] Brahmer J.R., Rodriguez-Abreu D., Robinson A. OA 17.06 Updated Analysis of KEYNOTE-024: Pem- brolizumab vs Platinum-based chemotherapy for advanced NSCLC With PD-L1 TPS 6 50 %. J Thorac Oncol. 2017;12:S1793-S1794. Suppl. 2
  • [20] Brahmer J.R., Rodriguez-Abreu D., Robinson A.G. Health-related quality-of-life results for pembroli- zumab chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, openlabel phase 3 trial. Lancet Oncol. 2017;18:1600-1609. versus12
  • [21] Carbone D.P., Reck M., Paz-Ares L. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017 22;376:2415-2426. 25
  • [22] Langer C.J., Gadgeel S.M., Borghaei H. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497-1508. 11
  • [23] Borghaei H., Langer C.J., Gadgeel S. Updated results from KEYNOTE-021 cohortG: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. Ann Oncol. 2017;28:LBA49. Suppl. 5
  • [24] Peters S., Carcereny Costa E., Garassino M.C. Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1-selected patients: Efficacy data from the BIRCH trial. Ann Oncol. 2017;28:840. Suppl. 2
  • [25] Fehrenbacher L., Spira A., Ballinger M. Atezolizumab docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837-1846. versus10030
  • [26] Weber J.S., Kahler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697. 21
  • [27] Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol ; 27 (4) : 559-74.
  • [28] Assi H.I., Kamphorst A.O., Moukalled N.M., Ramalingam S.S. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer. 2018;124:248-261. 2
  • [29] Haanen J.B.A.G., Carbonnel F., Robert C. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142. Suppl. 4